GLSI - שולי רווח נקי ממכירות Greenwich LifeSciences

Lack of profitability and dependence on investment during Phase III trials create a negative cash flow for Greenwich LifeSciences (GLSI). The net profit margin visualizes this financial burden, where 0.00 reflects the latest value of the metric. The situation is further complicated by micro-cap risks, insider dominance in management, and geopolitical barriers limiting access to international patient groups.
פילוחים אנליטיים ודוחות נתונים של חברת Greenwich LifeSciences, Inc (GLSI)

The selection of high-quality issuers is based on an analysis of how effectively revenue is converted into net income using a system of fundamental multiples. This metric determines the profit margin per dollar of sales, which, given the high bioengineering and GP2 vaccine R&D costs for Greenwich LifeSciences (GLSI), allows for the differentiation of the business's intrinsic value from market overheating through monthly sales margin dynamics.